Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Alpine Immune Sciences
(NASDAQ:ALPN)
Intraday
$64.56
-0.06
[-0.09%]
After-Hours
$64.56
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$64.56
-0.06
[-0.09%]
At close: Apr 26
$64.56
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Alpine Immune Sciences Stock (NASDAQ:ALPN)
Alpine Immune Sciences Stock (NASDAQ: ALPN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 26, 2024
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Vandana Singh
-
4 hours ago
Tuesday, April 16, 2024
TD Cowen Downgrades Alpine Immune Sciences to Hold
Benzinga Newsdesk
-
Apr 16, 2024, 6:49AM
Friday, April 12, 2024
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform, Raises Price Target to $65
Benzinga Newsdesk
-
Apr 12, 2024, 9:54AM
Thursday, April 11, 2024
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Vandana Singh
-
Apr 11, 2024, 2:47PM
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
Piero Cingari
-
Apr 11, 2024, 2:13PM
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Apr 11, 2024, 1:33PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Apr 11, 2024, 12:31PM
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
Apr 11, 2024, 10:01AM
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Vandana Singh
-
Apr 11, 2024, 9:01AM
Wedbush Downgrades Alpine Immune Sciences to Neutral
Benzinga Newsdesk
-
Apr 11, 2024, 8:18AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Apr 11, 2024, 8:10AM
Wolfe Research Downgrades Alpine Immune Sciences to Peer Perform
Benzinga Newsdesk
-
Apr 11, 2024, 8:02AM
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
Shanthi Rexaline
-
Apr 11, 2024, 7:27AM
Alpine Immune Sciences shares are trading higher after Vertex entered into an agreement to acquire the company.
Benzinga Newsdesk
-
Apr 11, 2024, 7:11AM
RBC Capital Downgrades Alpine Immune Sciences to Sector Perform, Raises Price Target to $65
Benzinga Newsdesk
-
Apr 11, 2024, 6:56AM
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Apr 11, 2024, 6:14AM
Morgan Stanley Downgrades Alpine Immune Sciences to Equal-Weight, Raises Price Target to $65
Benzinga Newsdesk
-
Apr 11, 2024, 5:46AM
Wednesday, April 10, 2024
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today
Benzinga Neuro
-
Apr 10, 2024, 10:19PM
Alpine Immune Sciences shares are trading higher after Vertex entered into an agreement to acquire the company.
Benzinga Newsdesk
-
Apr 10, 2024, 4:39PM
Alpine Immune Sciences Shares Resumed Trade
Benzinga Newsdesk
-
Apr 10, 2024, 4:31PM
Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk
-
Apr 10, 2024, 4:25PM
Alpine Immune Sciences Reports Updated Clinical Data From Povetacicept In IgA Nephropathy
Benzinga Newsdesk
-
Apr 10, 2024, 4:16PM
Vertex Subsidiary To Commence Cash Tender Offer To Purchase All Outstanding Shares Of Alpine Common Stock
Benzinga Newsdesk
-
Apr 10, 2024, 4:05PM
Vertex Enters Into Agreement To Acquire Alpine Immune Sciences For $65 Per Share Or Approximately $4.9B In Cash
Benzinga Newsdesk
-
Apr 10, 2024, 4:02PM
Trading Halt: Halted at 4:00:30 p.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk
-
Apr 10, 2024, 4:00PM
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
Vandana Singh
-
Apr 10, 2024, 3:07PM
Alpine Immune shares are trading higher following a report suggesting the company is weighing options including a potential sale after seeing takeover interest.
Benzinga Newsdesk
-
Apr 10, 2024, 1:27PM
Watching Vera Therapeutics; Traders Circulating Share Price Moved Higher In Sympathy With Alpine Immune Report Suggesting The Co Is Weighing Options After Takeover Interest
Benzinga Newsdesk
-
Apr 10, 2024, 12:53PM
'Alpine Immune Is Said To Weigh Options After Takeover Interest' - BNN Bloomberg
Benzinga Newsdesk
-
Apr 10, 2024, 12:40PM
Tuesday, April 09, 2024
Navigating 8 Analyst Ratings For Alpine Immune Sciences
Benzinga Insights
-
Apr 9, 2024, 9:00AM
Alpine Immune Sciences shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and $55 price target.
Benzinga Newsdesk
-
Apr 9, 2024, 8:27AM
Guggenheim Initiates Coverage On Alpine Immune Sciences with Buy Rating, Announces Price Target of $55
Benzinga Newsdesk
-
Apr 9, 2024, 7:01AM
Thursday, April 04, 2024
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
Avi Kapoor
-
Apr 4, 2024, 10:44AM
Monday, April 01, 2024
Alpine Immune Sciences To Present Updated Clinical Data For Povetacicept In IgA Nephropathy At The World Congress Of Nephrology 2024
Benzinga Newsdesk
-
Apr 1, 2024, 9:05AM
Thursday, March 21, 2024
HC Wainwright & Co. Maintains Buy on Alpine Immune Sciences, Maintains $50 Price Target
Benzinga Newsdesk
-
Mar 21, 2024, 11:24AM
Tuesday, March 19, 2024
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Mar 19, 2024, 1:48PM
Alpine Immune Sciences Analysts Boost Their Forecasts After Q4 Earnings
Avi Kapoor
-
Mar 19, 2024, 10:35AM
Alpine Immune Sciences shares are trading higher after the company reported better-than-expected Q4 financial results. Also, multiple firms raised their respective price targets on the stock.
Benzinga Newsdesk
-
Mar 19, 2024, 10:20AM
Morgan Stanley Maintains Overweight on Alpine Immune Sciences, Raises Price Target to $47
Benzinga Newsdesk
-
Mar 19, 2024, 10:18AM
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
-
Mar 19, 2024, 10:03AM
Evaluating Alpine Immune Sciences: Insights From 6 Financial Analysts
Benzinga Insights
-
Mar 19, 2024, 10:01AM
Wedbush Reiterates Outperform on Alpine Immune Sciences, Maintains $47 Price Target
Benzinga Newsdesk
-
Mar 19, 2024, 9:11AM
Oppenheimer Maintains Outperform on Alpine Immune Sciences, Raises Price Target to $44
Benzinga Newsdesk
-
Mar 19, 2024, 8:38AM
HC Wainwright & Co. Maintains Buy on Alpine Immune Sciences, Raises Price Target to $50
Benzinga Newsdesk
-
Mar 19, 2024, 6:29AM
Monday, March 18, 2024
Recap: Alpine Immune Sciences Q4 Earnings
Benzinga Insights
-
Mar 18, 2024, 4:50PM
Alpine Immune Sciences Q4 2023 GAAP EPS $0.15 Beats $(0.29) Estimate, Sales $30.853M Beat $9.104M Estimate
Benzinga Newsdesk
-
Mar 18, 2024, 4:47PM
Earnings Scheduled For March 18, 2024
Benzinga Insights
-
Mar 18, 2024, 5:57AM
Friday, March 15, 2024
Preview: Alpine Immune Sciences's Earnings
Benzinga Insights
-
Mar 15, 2024, 11:00AM
Tuesday, March 12, 2024
RBC Capital Maintains Outperform on Alpine Immune Sciences, Raises Price Target to $41
Benzinga Newsdesk
-
Mar 12, 2024, 10:45AM
Thursday, February 15, 2024
Wolfe Research Initiates Coverage On Alpine Immune Sciences with Outperform Rating
Benzinga Newsdesk
-
Feb 15, 2024, 6:16AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch